pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
BridgeBio Oncology Therapeutics projects
10 ClinicalTrials.gov programs sponsored by BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AG10
BridgeBio Oncology Therapeutics
Amyloid Cardiomyopathy
1 trial -
AG10
BridgeBio Oncology Therapeutics
Familial ATTR-CM (ATTRm-CM, or FAC)
1 trial -
BGJ398 (infigratinib)
BridgeBio Oncology Therapeutics
Advanced Cholangiocarcinoma
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Hypochondroplasia
1 trial -
Infigratinib 0.016 mg/kg
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Infigratinib is provided as a single dose of minitablets for oral administration
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
PTR-01
BridgeBio Oncology Therapeutics
Recessive Dystrophic Epidermolysis Bullosa
1 trial -
VT30
BridgeBio Oncology Therapeutics
Venous Malformation
1 trial -
encaleret
BridgeBio Oncology Therapeutics
Post-Surgical Hypoparathyroidism
1 trial
Frequently asked questions
How many clinical projects does BridgeBio Oncology Therapeutics have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.